Theravance Biopharma Inc (TBPH) Expected to Post Quarterly Sales of $12.32 Million

Brokerages forecast that Theravance Biopharma Inc (NASDAQ:TBPH) will report $12.32 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Theravance Biopharma’s earnings, with the highest sales estimate coming in at $13.96 million and the lowest estimate coming in at $10.40 million. Theravance Biopharma posted sales of $4.52 million in the same quarter last year, which would indicate a positive year over year growth rate of 172.6%. The business is expected to issue its next earnings results on Tuesday, February 26th.

On average, analysts expect that Theravance Biopharma will report full year sales of $57.86 million for the current fiscal year, with estimates ranging from $55.00 million to $60.00 million. For the next year, analysts forecast that the business will report sales of $75.73 million, with estimates ranging from $56.30 million to $100.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.18) by $0.08. The firm had revenue of $12.84 million for the quarter, compared to the consensus estimate of $10.55 million. Theravance Biopharma had a negative net margin of 513.41% and a negative return on equity of 505.90%.

Several research firms have commented on TBPH. BidaskClub raised shares of Theravance Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 25th. ValuEngine downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Thursday, November 1st. Leerink Swann set a $38.00 target price on shares of Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Zacks Investment Research downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 10th. Finally, Cantor Fitzgerald began coverage on shares of Theravance Biopharma in a research report on Monday, January 28th. They set a “buy” rating and a $55.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Theravance Biopharma has a consensus rating of “Hold” and an average price target of $43.40.

A number of hedge funds have recently added to or reduced their stakes in TBPH. FNY Investment Advisers LLC bought a new stake in Theravance Biopharma during the fourth quarter valued at about $42,000. Quantamental Technologies LLC bought a new stake in Theravance Biopharma during the fourth quarter valued at about $102,000. United Services Automobile Association bought a new stake in Theravance Biopharma during the third quarter valued at about $210,000. Xact Kapitalforvaltning AB bought a new stake in Theravance Biopharma during the third quarter valued at about $285,000. Finally, Man Group plc bought a new stake in Theravance Biopharma during the third quarter valued at about $292,000. Institutional investors own 83.94% of the company’s stock.

Theravance Biopharma stock traded up $1.07 during mid-day trading on Friday, hitting $27.12. 118,998 shares of the company’s stock were exchanged, compared to its average volume of 157,139. The company has a debt-to-equity ratio of 6.52, a current ratio of 3.26 and a quick ratio of 3.08. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of -4.98 and a beta of 1.75. Theravance Biopharma has a 1-year low of $21.27 and a 1-year high of $35.48.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.

Read More: What are retained earnings?

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit